Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Taiho Picks Up Rights to China Pharma’s Lung Cancer Drug
Taiho Pharmaceutical said on March 1 that it has snared the exclusive rights to Haihe Biopharma’s gumarontinib, a drug candidate for non-small cell lung cancer (NSCLC) now under Japanese regulatory review, in Japan, Asia (excluding China), and Oceania. The Otsuka…
To read the full story
Related Article
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
- Toho Confirms Preliminary Bid for PHC as It Mulls Buyout
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…